secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001193125-22-141306
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios reports Q1 net loss $94.8M; PYRUKYND launch revenue $0.8M, cash $1.2B
---------------------------------------------------------------------------

- FDA approved PYRUKYND for PK deficiency in Feb 2022; U.S. launch generated $0.8M net revenue in partial quarter.
- Net loss from continuing ops $94.8M vs $90.9M YoY; R&D spend $70.1M, SG&A $31.5M.
- Cash & securities $1.2B (down from $2.4B YoY) due to $802.5M share repurchases in 2021; no need for equity.
- Key 2022 milestones: EMA decision on PYRUKYND by year-end, start pediatric PK studies mid-2022.
- Phase 2a study of AG-946 in MDS to initiate by year-end; AG-946 Phase 1 sickle cell cohort started.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522141306/0001193125-22-141306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522141306/d266362d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-141306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer